Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer

Roy S. Herbst, S. Gail Eckhardt, Razelle Kurzrock, +10

Journal of Clinical Oncology

Clinical pharmacokinetics of bevacizumab in patients with solid tumors

Jianfeng Lü, René Bruno, Steve Eppler, +3

Cancer Chemotherapy and Pharmacology

OncologyMedicinePharmacotherapyClinical PharmacokineticsCancer Treatment +1

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

Gustavo Ismael, Roberto Hegg, Susanne Muehlbauer, +7

The Lancet Oncology

Hannah StudyBreast OncologyOncologyBreast CancerAdjuvant Trastuzumab +4

Mitoxantrone, Etoposide, and Cytarabine With or Without Valspodar in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995)

Peter L. Greenberg, Sandra J. Lee, Ranjana H. Advani, +10

Journal of Clinical Oncology

METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERS

Jie Ling, Kim A. Johnson, Zhuang Miao, +5

Drug Metabolism and Disposition

Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas.

Quynh‐Thu Le, Patrick D. Sutphin, Soumya Raychaudhuri, +7

PubMed

Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy.

Frank M. Torti, Michael M. Bristow, Bert L. Lum, +7

PubMed

Myofibrillar LossHeart FailureCardiomyopathyCardiogenic ShockCardiovascular Disease +11

Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drug–Drug Interaction Potential for Molecular Targeted Agents in Clinical Development

Gillian S. Smelick, Timothy P. Heffron, Laura Chu, +10

Molecular Pharmaceutics

Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer

Tony Reid, Frank H. Valone, William LiPera, +8

Lung Cancer

Phase Ii TrialMedicinePharmacologyBronchial NeoplasmAnti-cancer Agent +5

Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar)

Ranjana H. Advani, Hussain I. Saba, Martin S. Tallman, +11

Blood